Opdivo plus Yervoy and SBRT in Refractory Metastatic Pancreatic Cancer: CheckPAC Trial
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On April 27, 2022, Inna M. Chen and colleagues from Copenhagen University Hospital published the results of the CheckPAC Phase 2 clinical trial in the Journal of Clinical Oncology. The study explored a novel combination of immunotherapy and radiation for patients with metastatic pancreatic cancer who had failed previous treatments.
Study Design: CheckPAC Trial
The trial randomized 84 patients with refractory metastatic pancreatic cancer into two groups:
- Opdivo + SBRT Group (N=41): Nivolumab monotherapy combined with stereotactic body radiotherapy.
- Opdivo + Yervoy + SBRT Group (N=43): Nivolumab and Ipilimumab combined with SBRT.
The primary endpoint was clinical benefit rate (CBR), defined as complete response, partial response, or stable disease for at least 12 weeks.
Key Results
The addition of Yervoy significantly improved outcomes:
- Clinical Benefit Rate (CBR):
- Combination Group (Nivo+Ipi+SBRT): 37.2%
- Monotherapy Group (Nivo+SBRT): 17.1%
- Partial Response Rate: 6 patients in the combination group vs. 1 patient in the monotherapy group.
- Median Duration of Response: 5.4 months for the combination group.
Safety Profile
The incidence of Grade 3 or higher adverse events was 30.2% in the combination group compared to 24.4% in the monotherapy group. The side effects were generally manageable and consistent with the known profiles of these immunotherapies.
Conclusion
The CheckPAC trial demonstrated that the combination of Opdivo, Yervoy, and SBRT achieves an encouraging clinical benefit rate in patients with refractory metastatic pancreatic cancer. While immunotherapy has historically been less effective in pancreatic cancer, these results suggest that combining dual checkpoint inhibition with radiation may overcome some of the immune resistance in this disease. Further studies are needed to refine this approach.
Source: Journal of Clinical Oncology - CheckPAC Trial Results
#PancreaticCancer #Opdivo #Nivolumab #Yervoy #Ipilimumab #SBRT #CheckPAC #Immunotherapy #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4